ES2133412T3 - 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma. - Google Patents

2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.

Info

Publication number
ES2133412T3
ES2133412T3 ES93920816T ES93920816T ES2133412T3 ES 2133412 T3 ES2133412 T3 ES 2133412T3 ES 93920816 T ES93920816 T ES 93920816T ES 93920816 T ES93920816 T ES 93920816T ES 2133412 T3 ES2133412 T3 ES 2133412T3
Authority
ES
Spain
Prior art keywords
cyclophosphates
oligoadenylates
oligoadenylate
activity
papiloma virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920816T
Other languages
English (en)
Inventor
Edward I Budowsky
Alexander E Gavrilov
Arman D Pivasyan
Alexander Zhelkowsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2133412T3 publication Critical patent/ES2133412T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

EL OBJETO DE LA INVENCION SON NUEVOS 2 '' ,5 '' OLIGOADENILATOS-2{SUP,''},3{SUP,''}-CICLOFOSFATOS DE FORMULA (I), DONDE 0 <= N <= 10, ESPECIALMENTE 1 O 2, PARA MEDICAMENTOS QUE LLEVAN ESTOS PRINCIPIOS ACTIVOS Y SU UTILIZACION.
ES93920816T 1993-09-24 1993-09-24 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma. Expired - Lifetime ES2133412T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1993/002596 WO1995008555A1 (de) 1993-09-24 1993-09-24 2',5'-oligoadenylat-2',3'-cyclophosphate

Publications (1)

Publication Number Publication Date
ES2133412T3 true ES2133412T3 (es) 1999-09-16

Family

ID=8165765

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920816T Expired - Lifetime ES2133412T3 (es) 1993-09-24 1993-09-24 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.

Country Status (9)

Country Link
US (2) US5739013A (es)
EP (1) EP0721457B1 (es)
JP (1) JPH09509647A (es)
KR (1) KR100332250B1 (es)
DE (1) DE69324826D1 (es)
DK (1) DK0721457T3 (es)
ES (1) ES2133412T3 (es)
GR (1) GR3030863T3 (es)
WO (1) WO1995008555A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
DK0721457T3 (da) * 1993-09-24 1999-11-08 Edward I Budowsky 2',5'-Oligoadenylat-2',3'-cyclophosphater og 2',5'-oligo-adenylater med antipapillomavirusaktivitet
US5955446A (en) * 1997-01-16 1999-09-21 Pentose Pharmaceuticals, Inc. Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US7498156B2 (en) * 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US7049110B2 (en) * 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
JP2002541822A (ja) * 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
JP2003510281A (ja) * 1999-09-29 2003-03-18 ザ クリーブランド クリニック ファウンデーション 2−5aおよびインターフェロンを用いる治療
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US7648699B2 (en) * 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
TW590780B (en) * 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US7985588B2 (en) * 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US6843961B2 (en) * 2000-06-15 2005-01-18 Gambro, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US20020123480A1 (en) * 2000-10-24 2002-09-05 Edson Clark M. Methods and compositions utilizing 2'-5' oligoadenylates in the treatment of disorders of cell proliferation
JP2005537028A (ja) * 2002-06-26 2005-12-08 ザ ペン ステート リサーチ ファウンデーション ヒト乳頭腫ウイルス感染症を治療する方法及び材料
US7134395B2 (en) * 2004-01-20 2006-11-14 Southern Lithoplate, Inc. Acid inkjet imaging of lithographic printing plates
KR20210062430A (ko) 2019-11-21 2021-05-31 대한민국(전북기계공업고등학교장) 동력 전달 장치를 활용한 교육 시스템

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312891A (en) * 1976-07-23 1978-02-04 Kikkoman Corp Novel 1,n6-etheno-2-substituted-adenosine-3,5-cyclic phosphoric acid
IL58421A (en) * 1979-10-09 1984-01-31 Yeda Res & Dev Production of(2'-5')oligoisoadenylate and pharmaceutical compositions containing it
US4859768A (en) * 1984-07-11 1989-08-22 Temple University Of The Commonwealth System Of Higher Education Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
DE4211238C2 (de) * 1992-04-03 1994-10-27 Edward I Budowskij Verwendung von 2',5'-Oligoadenylaten zur Behandlung von Papillomatosen
DK0721457T3 (da) * 1993-09-24 1999-11-08 Edward I Budowsky 2',5'-Oligoadenylat-2',3'-cyclophosphater og 2',5'-oligo-adenylater med antipapillomavirusaktivitet

Also Published As

Publication number Publication date
JPH09509647A (ja) 1997-09-30
WO1995008555A1 (de) 1995-03-30
EP0721457A1 (de) 1996-07-17
US5962431A (en) 1999-10-05
DK0721457T3 (da) 1999-11-08
GR3030863T3 (en) 1999-11-30
EP0721457B1 (de) 1999-05-06
DE69324826D1 (de) 1999-06-10
KR960704911A (ko) 1996-10-09
KR100332250B1 (ko) 2002-12-05
US5739013A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
ES2133412T3 (es) 2&#39;,5&#39;-oligoadenilato-2&#39;,3&#39;-ciclofosfatos y 2&#39;,5&#39;-oligoadenilatos con actividad sobre el virus papiloma.
ES2164182T3 (es) Benzociclopentanoxazolidinonas que contienen heteroatomos con actividad antibacteriana.
ES2195970T3 (es) L-ribavirina y usos de la misma.
DE69334186D1 (de) Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
NO307336B1 (no) 2-[(Dihydro)pyrazolyl-3&#39;-oksylmetylen]anilider, anvendelse derav, samt middel inneholdende forbindelsen og mellomprodukter for fremstilling av forbindelsen
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
ES2093979T3 (es) Esteres nitricos de derivados del acido 2-(2,6-dihalofenilamino)fenilacetico y su procedimiento de preparacion.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69432984D1 (de) Therapeutische substituierte guanidine
IT1285770B1 (it) Composti corticoidei
ES2056180T3 (es) Nuevos derivados de 2&#39;-halometiliden, 2&#39;-eteniliden y 2&#39;-etinil citidina.
ES2170822T3 (es) Formulacion liquida de 1,2-bencisotiazolin-3-ona.
ES2136725T3 (es) Utilizacion de 2-amino-6-n-propil-amino-4,5,6,7-tetrahidrobenzotiazol (pramipexol) como medicamento con efecto antidepresivo.
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
BR0007514A (pt) Macrolìdeos com atividade anti-inflamatória
IT9019754A0 (it) Composizioni farmaceutiche,dietetiche o veterinarie ad attivita&#39; eumetabolica
ITMI921551A1 (it) Glutatione come agente chemioprotettivo
AR009809A1 (es) Derivados de 10,13,15-trioxatriciclo[9.2.1(9.6)]-pentadecanona, procedimientos para su preparacion y medicamentos que contienen estos compuestos
TR199901209T2 (xx) B�cek �ld�r�c� ve mitisidal kompozisyonlar
PA7801701A1 (es) Compuestos ariltios
ATE28188T1 (de) Antikonvulsive mittel.
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
ES2152315T3 (es) Xamoneline tartrato.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 721457

Country of ref document: ES